NCT04809584 2024-12-19
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Stanford University
Approved for marketing
Clinical Trials
13 trialsNCT00906984 2024-01-08
TheraSphere
University of California, Irvine
Approved for marketing
NCT00872950 2022-04-11
LEMS
Lahey Clinic
Approved for marketing
NCT04452136 2022-03-14
Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer
OHSU Knight Cancer Institute
Approved for marketing
NCT01825395 2021-10-06
3 4-DAP
University of Colorado, Denver
Approved for marketing
NCT04348682 2021-06-24
Expanded Access Protocol of 68Ga-PSMA-11 for PET Imaging
Jonsson Comprehensive Cancer Center
Approved for marketing
NCT04377152 2021-03-01
Expanded Access 68Gallium-PSMA-11 PET for Prostate Cancer
University of California, San Francisco
Approved for marketing
NCT01480128 2020-06-19
SIMPLE
The Catholic University of Korea
Approved for marketing
NCT01377532 2020-05-06
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
University of California, San Francisco
Approved for marketing
NCT02436044 2019-08-20
HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC
Sun Yat-sen University
Approved for marketing
NCT01869803 2018-03-02
Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia
Wake Forest University Health Sciences
Approved for marketing
NCT02355054 2017-01-20
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
Washington University School of Medicine
Approved for marketing
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing